Ignite Creation Date:
2024-05-06 @ 2:29 PM
Last Modification Date:
2024-10-26 @ 1:32 PM
Study NCT ID:
NCT04333407
Status:
TERMINATED
Last Update Posted:
2023-01-18
First Post:
2020-04-01
Brief Title:
Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy A Randomised Controlled Trial
Sponsor:
Imperial College London
Organization:
Imperial College London
Study Overview
Official Title:
Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy A Randomised Controlled Trial
Status:
TERMINATED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Difficulty in recruiting eligible participants
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
C-19-ACS
Brief Summary:
The outbreak of a novel coronavirus SARS-CoV-2 and associated COVID-19 disease in late December 2019 has led to a global pandemic At the time of writing there have been 150 000 confirmed cases and 3500 deaths Apart from the morbidity and mortality directly related to COVID-19 cases society has had to also cope with complex political and economic repercussions of this disease
At present and despite pressing need for therapeutic intervention management of patients with COVID-19 is entirely supportive Despite the majority of patients experiencing a mild respiratory illness a subgroup and in particular those with pre-existing cardiovascular disease will experience severe illness that requires invasive cardiorespiratory support in the intensive care unit
Furthermore the severity of COVID-19 disease as well as the likelihood of progressing to severe disease appears to be in part driven by direct injury to the cardiovascular system Analysis of data from two recent studies confirms a significantly higher likelihood of acute cardiac injury in patients who have to be admitted to intensive care for the management of COVID-19 disease
The exact type of acute of cardiac injury that COVID-19 patients suffer remains unclear There is however mounting evidence that heart attack like events are responsible Tests ordinarily performed to definitely assess for heart attacks will not be possible in very sick COVID-19 patients Randomising patients to cardioprotective medicines will help us understand the role of the cardiovascular system in COVID-19 disease It will also help us determine if there is more we can do to treat these patients
At present and despite pressing need for therapeutic intervention management of patients with COVID-19 is entirely supportive Despite the majority of patients experiencing a mild respiratory illness a subgroup and in particular those with pre-existing cardiovascular disease will experience severe illness that requires invasive cardiorespiratory support in the intensive care unit
Furthermore the severity of COVID-19 disease as well as the likelihood of progressing to severe disease appears to be in part driven by direct injury to the cardiovascular system Analysis of data from two recent studies confirms a significantly higher likelihood of acute cardiac injury in patients who have to be admitted to intensive care for the management of COVID-19 disease
The exact type of acute of cardiac injury that COVID-19 patients suffer remains unclear There is however mounting evidence that heart attack like events are responsible Tests ordinarily performed to definitely assess for heart attacks will not be possible in very sick COVID-19 patients Randomising patients to cardioprotective medicines will help us understand the role of the cardiovascular system in COVID-19 disease It will also help us determine if there is more we can do to treat these patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None